Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Research & Development (2020 - 2025)

Foghorn Therapeutics has reported Research & Development over the past 6 years, most recently at $22.0 million for Q4 2025.

  • Quarterly results put Research & Development at $22.0 million for Q4 2025, up 7.5% from a year ago — trailing twelve months through Dec 2025 was $85.5 million (down 9.59% YoY), and the annual figure for FY2025 was $85.5 million, down 9.59%.
  • Research & Development for Q4 2025 was $22.0 million at Foghorn Therapeutics, up from $20.0 million in the prior quarter.
  • Over the last five years, Research & Development for FHTX hit a ceiling of $30.0 million in Q1 2023 and a floor of $18.6 million in Q2 2021.
  • Median Research & Development over the past 5 years was $24.0 million (2023), compared with a mean of $23.8 million.
  • Biggest five-year swings in Research & Development: soared 62.79% in 2021 and later decreased 18.98% in 2025.
  • Foghorn Therapeutics' Research & Development stood at $22.5 million in 2021, then increased by 25.58% to $28.2 million in 2022, then fell by 14.19% to $24.2 million in 2023, then dropped by 15.27% to $20.5 million in 2024, then rose by 7.5% to $22.0 million in 2025.
  • The last three reported values for Research & Development were $22.0 million (Q4 2025), $20.0 million (Q3 2025), and $21.8 million (Q2 2025) per Business Quant data.